查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931237

人類副流感病毒檢測套組市場（按產品、技術、最終用戶、樣本類型和應用分類）－全球預測，2026-2032年

Human Parainfluenza Virus Test Kits Market by Product, Technology, End User, Sample Type, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年人類副流感病毒檢測套組市值為 2.9598 億美元，預計到 2026 年將成長至 3.1686 億美元，預計到 2032 年將達到 4.7622 億美元，複合年成長率為 7.03%。

關鍵市場統計數據
基準年 2025 2.9598億美元
預計年份：2026年 3.1686億美元
預測年份 2032 4.7622億美元
複合年成長率 (%) 7.03%

人類副流感病毒診斷的全面概述：為決策者闡明目的、主要讀者、範圍和實際背景

鑑於人類副流感病毒的普遍性和臨床意義，需要一份清晰易懂的概述，以明確臨床和公共衛生相關人員的診斷重點。本導言闡明了報告的目的，明確了主要讀者——臨床醫生、檢查室主任、診斷開發人員和政策顧問——並概述了報告涵蓋的技術模式、產品形式、終端用戶環境、檢體類型和應用領域。此外，本導言也表明，報告著重於營運和策略方面的見解，而非抽象的統計預測。

技術創新、監管調整和供應鏈韌性如何推動副流感診斷策略和部署的變革性變化

技術進步、臨床需求變化以及公共衛生重點的演變正在重塑副流感病毒的診斷模式。檢測化學、儀器小型化和檢體自動化處理的最新趨勢正在加速向更快速、更一體化的診斷工作流程轉變。同時，呼吸道症候群多重檢測的日益普及也影響著檢測設計和採購的考量，人們期望副流感病毒檢測能夠與流感病毒、呼吸道合胞病毒（RSV）和新興病原體檢測組合相容。

評估美國近期關稅調整對診斷試劑盒生產、採購和檢查室供應策略的營運和採購影響

美國近期採取的關稅措施為診斷試劑盒和試劑的製造商、經銷商和最終用戶帶來了多重考慮。關稅調整將影響進口零件（例如一次性塑膠製品、特殊酵素和儀器零件）的到岸成本，進而可能影響採購時機、庫存策略和生產本地化等方面的決策。因此，各機構正在重新審視供應商合約和籌資策略，以應對成本波動，同時確保關鍵投入品的持續供應。

將技術、產品分類、終端用戶環境、檢體基質和應用領域與診斷決策聯繫起來的詳細細分分析

深入了解技術和產品細分對於使診斷開發和採購策略與臨床及營運需求保持一致至關重要。基於技術的分類可分為免疫檢測和分子診斷。免疫檢測包括化學冷光免疫檢測、酵素免疫分析法和側向流動免疫檢測，每種方法在通量、靈敏度和照護現場適用性方面各有優劣。分子方法包括等溫擴增、次世代定序和即時PCR，每種方法在分析解析度、多重檢測能力和檢查室複雜度方面各有不同。

區域法規結構、醫療基礎設施多樣性和生產能力將如何影響全球市場副流感診斷的策略決策

區域趨勢將在決定全球醫療系統中診斷技術的可用性、監管路徑和應用模式方面發揮關鍵作用。在美洲，成熟的實驗室網路和完善的採購流程正在促進高通量分子平台和檢驗的照護現場方案的整合，重點在於互通性和數據連接性，以支援臨床決策。在歐洲、中東和非洲地區，不同的法規結構和醫療基礎設施導致了不同的應用模式。一些市場優先考慮集中式檢查室檢測和嚴格的合格評定，而另一些市場則越來越依賴分散式解決方案，以擴大資源匱乏地區的醫療服務覆蓋範圍。

產業競爭與合作趨勢凸顯了平台柔軟性、夥伴關係策略與服務導向模式對副流感診斷的影響。

診斷公司之間的競爭持續加速產品創新、夥伴關係活動和策略整合。主要企業正投資於平台柔軟性，以同時滿足照護現場和集中式檢查室的需求，優先考慮模組化儀器設計和可適用於各種呼吸道檢測專案的檢測化學方法。檢測開發人員和儀器製造商之間的策略聯盟正在加速需要整合檢體處理和數位化讀數的檢測方法的臨床應用。同時，以服務為導向的經營模式強調遠端監控、培訓和耗材補充，以保障收入來源和客戶運作。

產業領導者可以採取哪些切實可行的策略重點和營運措施來增強診斷能力、提高供應鏈韌性並加強監管準備？

為了掌握診斷領域的機會並降低營運風險，產業領導者應採取切實可行的優先事項。首先，優先驗證所有預期檢體類型和終端使用者環境下的檢測檢驗，以確保效能穩定可靠，並能輕鬆整合到臨床工作流程中。其次，拓展供應商關係，並考慮採用模組化生產策略，以降低單點故障風險，同時確保品質和合規性。第三，增加對平台互通性和連接性的投資，以滿足醫療系統對無縫資料交換的需求，並支援多病原體檢測策略。

一種透明且可複製的調查方法，結合了對關鍵相關人員的訪談、技術文獻綜述和基於情境的供應鏈分析。

本報告的調查方法結合了多方面的證據綜合、專家諮詢和系統性檢驗，旨在得出切實可行的見解。主要研究包括對臨床實驗室主任、診斷研發負責人、採購專業人員和公共衛生從業人員的訪談，以確保研究結果與實際情況緊密結合。次要研究則利用了同行評審文獻、監管指南、技術白皮書和產品文檔，以支持對技術性能特徵、工作流程影響和監管路徑的分析。

一份簡明扼要的摘要，重點闡述了整合技術效能、工作流程相容性和供應鏈彈性的持續診斷的影響。

總之，副流感病毒診斷正朝著分析嚴謹性和操作實用性之間的平衡發展。免疫檢測和分子診斷技術的進步、照護現場（POC​​）能力的提升以及供應鏈意識的增強，共同推動著檢測方法的設計、檢驗和部署方式的變革。因此，相關人員必須將技術效能與工作流程相容性、法規遵循和採購韌性等因素結合，才能達到持續的臨床應用效果。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 人類副流感病毒檢測套組市場（依產品分類）

  • 等溫套件
  • 快速檢測套組
  • 即時PCR試劑盒

9. 按技術分類的人類副流感病毒檢測套組市場

  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 側向流動免疫檢測
  • 分子
    • 等溫擴增
    • 次世代定序
    • 即時PCR

第10章 人類副流感病毒檢測套組市場（依最終用戶分類）

  • 學術研究機構
  • 診斷檢查室
  • 醫院
  • 照護現場中心

第11章：按檢體類型分類的人類副流感病毒檢測套組市場

  • 鼻咽拭子
  • 口咽拭子
  • 痰

第12章 人類副流感病毒檢測套組市場（依應用分類）

  • 臨床診斷
  • 流行病學調查
  • 調查

第13章 各地區人類副流感病毒檢測套組市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 人類副流感病毒檢測套組市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國人副流感病毒檢測套組市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國人類副流感病毒檢測套組市場

第17章：中國人副流感病毒檢測套組市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Anatolia Tani ve Biyoteknoloji Urunleri Sanayi ve Ticaret AS
  • Becton, Dickinson and Company
  • Beijing OriginGene-Tech Biotechnology Co.,Ltd
  • BioFire Diagnostics
  • bioMerieux SA
  • Certest Biotec
  • Cortez Diagnostics
  • Daan Gene Co., Ltd.
  • DBLue Medical
  • Genematrix Inc.
  • GenMark Diagnostics, Inc.
  • Hologic Inc.
  • Huwel Lifesciences
  • Luminex Corporation
  • QIAGEN NV
  • QuidelOrtho
  • R-Biopharm AG
  • Roche Holding AG
  • Seegene
  • Thermo Fisher Scientific
  • Xian Tianlong Science and Technology
  • Zhejiang Orient Gene
Product Code: MRR-7B550E008DD9

The Human Parainfluenza Virus Test Kits Market was valued at USD 295.98 million in 2025 and is projected to grow to USD 316.86 million in 2026, with a CAGR of 7.03%, reaching USD 476.22 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 295.98 million
Estimated Year [2026] USD 316.86 million
Forecast Year [2032] USD 476.22 million
CAGR (%) 7.03%

Comprehensive orientation to human parainfluenza virus diagnostics that clarifies purpose, audience, scope, and practical context for decision-makers

The prevalence and clinical significance of human parainfluenza viruses require a clear, accessible briefing that frames diagnostic priorities for clinical and public health stakeholders. This introduction establishes the purpose of the report, clarifies the intended audience of clinicians, laboratory directors, diagnostic developers, and policy advisors, and outlines the scope of coverage across technological modalities, product formats, end-user environments, sample types, and applications. It also signals the report's emphasis on operational and strategic insights rather than abstract statistical projections.

By situating parainfluenza testing within contemporary diagnostic pathways and recent shifts in respiratory pathogen detection, the introduction provides a concise orientation to the diagnostic challenges and opportunities. It highlights the interplay between rapid point-of-care decision-making and laboratory-based confirmatory workflows, and it underscores how diagnostic performance, workflow integration, regulatory constraints, and supply chain robustness shape deployment choices. Taken together, this opening section ensures readers are equipped to interpret subsequent analysis and apply findings to procurement, development, and clinical pathway design.

How technological innovation, regulatory adaptation, and supply chain resilience are driving transformative shifts in parainfluenza diagnostic strategies and deployment

Technological advances, shifting clinical expectations, and evolving public health priorities are reshaping the diagnostic landscape for parainfluenza viruses. Recent developments in assay chemistry, instrumentation miniaturization, and automated sample processing have accelerated the move toward faster, more integrated diagnostic workflows. In tandem, the prioritization of multiplex testing for respiratory syndromes has increased expectations that parainfluenza assays will interoperate with panels for influenza, RSV, and emergent pathogens, thereby influencing test design and purchasing considerations.

Concurrently, regulatory environments and reimbursement pathways have adapted to prioritize diagnostic responsiveness during respiratory seasons and outbreak events, creating pressure for assays that can demonstrate robust sensitivity and specificity across diverse sample types. The continued expansion of point-of-care testing capabilities, supported by simplified user interfaces and connectivity features for electronic health records, is enabling broader deployment in emergency departments, urgent care centers, and decentralized clinics. These dynamics are complemented by supply chain resilience initiatives that emphasize diversified reagent sources, modular instrument platforms, and onshore production capacity to mitigate disruption risks. Together, these shifts are prompting both incremental and transformative changes in how diagnostics are developed, validated, and adopted across care settings.

Assessing the operational and procurement consequences of recent United States tariff adjustments on diagnostic kit production, sourcing, and laboratory supply strategies

Recent tariff actions in the United States have introduced a layered set of considerations for manufacturers, distributors, and end users of diagnostic kits and reagents. Tariff adjustments affect the landed cost of imported components such as plastic disposables, specialized enzymes, and instrument parts, and they can influence decisions about procurement timing, inventory strategies, and localization of manufacturing. As a result, organizations have been reexamining supplier contracts and sourcing strategies to manage cost volatility while maintaining uninterrupted access to critical inputs.

In practical terms, higher import levies increase the imperative for suppliers to pursue cost-saving process innovations and negotiate longer-term supply agreements. Stakeholders are balancing these pressures against the need to preserve assay quality and regulatory compliance, recognizing that substitution of inputs or changes to manufacturing sites may require additional validation and regulatory communication. For healthcare providers and laboratories, tariff-driven cost shifts can lead to re-prioritization of test menus and renegotiation of purchasing terms, while procurement teams weigh the trade-offs between near-term cost containment and long-term resilience. Looking ahead, the tariff environment is likely to be an ongoing operational consideration that shapes procurement cycles, supplier diversification strategies, and conversations about domestic manufacturing investment.

In-depth segmentation analysis linking technologies, product classes, end-user environments, sample matrices, and application domains to diagnostic decision-making

A granular understanding of technological and product segmentation is essential to align diagnostic development and purchasing strategies with clinical and operational needs. Based on technology, the landscape divides into Immunoassay and Molecular approaches. Immunoassay methodologies include chemiluminescence immunoassay, enzyme linked immunosorbent assay, and lateral flow immunoassay, each offering distinct trade-offs in throughput, sensitivity, and suitability for point-of-care use. Molecular methods encompass isothermal amplification, next generation sequencing, and real time PCR, providing varying depth of analytical resolution, multiplexing capacity, and laboratory complexity.

From a product perspective, diagnostic offerings are typically categorized as isothermal kits, rapid test kits, and real time PCR kits, which align with differing operational priorities such as turnaround time, analytical sensitivity, and integration with laboratory information systems. End-user segmentation highlights that academic and research institutes, diagnostic laboratories, hospitals, and point of care centers require tailored assay characteristics, validation support, and service models; academic and research settings often demand flexible platforms for exploratory studies, while hospitals prioritize throughput and robustness, and point of care centers emphasize ease of use and immediate actionable results. Sample-type considerations-nasopharyngeal swab, oropharyngeal swab, and sputum-affect pre-analytical handling, biosafety protocols, and assay sensitivity profiles, requiring developers to validate performance across relevant matrices. Finally, application-driven segmentation separates clinical diagnosis, epidemiological surveillance, and research use, each imposing distinct requirements for regulatory documentation, data reporting, and long-term specimen archiving. Understanding these segment boundaries enables stakeholders to match diagnostic attributes to clinical workflows and policy objectives in a way that optimizes clinical utility and operational efficiency.

How regional regulatory frameworks, healthcare infrastructure diversity, and manufacturing capacity shape strategic decisions for parainfluenza diagnostics across global markets

Regional dynamics play a decisive role in shaping diagnostics availability, regulatory pathways, and adoption patterns across global healthcare systems. The Americas exhibit mature laboratory networks and established procurement channels that favor integration of high-throughput molecular platforms and validated point-of-care solutions, with emphasis on interoperability and data connectivity for clinical decision support. Europe, the Middle East & Africa feature a heterogeneous set of regulatory frameworks and healthcare infrastructures that drive diverse adoption patterns: some markets prioritize centralized laboratory testing and stringent conformity assessments, while others increasingly rely on decentralized solutions to expand access in under-resourced areas.

In the Asia-Pacific region, strong domestic manufacturing capabilities, rapid adoption of automation, and robust public health testing programs support a dynamic environment for both innovative assay development and scaled distribution. Across regions, differences in reimbursement, laboratory accreditation standards, and supply chain architecture influence how diagnostic manufacturers prioritize regulatory filings, distribution partnerships, and local service models. Moreover, regional public health priorities and seasonal respiratory patterns shape demand planning and the types of assays that gain traction in clinical practice, requiring stakeholders to tailor commercial and operational strategies to regional nuances while maintaining core performance and compliance standards.

Competitive and collaborative industry trends highlighting platform flexibility, partnership strategies, and service-oriented models influencing parainfluenza diagnostics

Competitive dynamics among diagnostic companies continue to accelerate product innovation, partnership activity, and strategic consolidation. Leading firms are investing in platform flexibility that supports both point-of-care and centralized laboratory deployments, prioritizing modular instrument designs and assay chemistries that can be adapted across respiratory panels. Strategic collaborations between assay developers and instrument manufacturers are facilitating faster time-to-clinical-use for assays that require integrated sample processing and digital readouts, while service-oriented business models emphasize remote monitoring, training, and consumable replenishment to protect revenue streams and customer uptime.

In parallel, nimble developers are differentiating through focused specialization on rapid test formats or cutting-edge molecular methods such as isothermal amplification and sequencing-based approaches that provide enhanced resolution for surveillance and research applications. Procurement and clinical laboratory leaders are responding by demanding robust post-market support, transparent performance data across relevant sample types, and clear pathways for regulatory compliance. This environment is driving a blend of competition and cooperation where cross-licensing, distribution partnerships, and localized manufacturing agreements are common strategies to accelerate market access and sustain supply continuity.

Practical strategic priorities and operational actions that industry leaders can implement to strengthen diagnostics performance, supply resilience, and regulatory readiness

To capitalize on diagnostic opportunities while mitigating operational risks, industry leaders should adopt a set of pragmatic, actionable priorities. First, prioritize assay validation across the full range of anticipated sample types and end-user environments to ensure consistent performance and ease of integration into clinical workflows. Second, diversify supplier relationships and consider modular manufacturing strategies that reduce exposure to single-point disruptions while preserving quality and regulatory compliance. Third, invest in platform interoperability and connectivity to meet healthcare system demands for seamless data exchange and to support multi-pathogen testing strategies.

Additionally, companies should pursue regulatory engagement early in the product lifecycle to clarify documentation expectations and to expedite market access. Commercial teams should align product portfolios with regional needs, offering differentiated service models for high-volume laboratories versus decentralized point-of-care settings. Finally, cultivate partnerships with public health authorities and research institutions to validate assay utility in surveillance and outbreak contexts, thereby reinforcing the public health value proposition and strengthening institutional relationships that support long-term adoption.

Transparent and reproducible research methodology combining primary stakeholder interviews, technical literature synthesis, and scenario-based supply chain analysis

The research methodology underpinning this report combines multi-source evidence synthesis, expert consultation, and structured validation to produce actionable insights. Primary research included interviews with clinical laboratory directors, diagnostic development leaders, procurement specialists, and public health practitioners to ground findings in operational realities. Secondary research drew on peer-reviewed literature, regulatory guidance, technical whitepapers, and product documentation to corroborate technology performance characteristics, workflow implications, and regulatory pathways.

Analytical techniques incorporated comparative technology assessment, value chain mapping, and scenario-based supply chain stress testing to explore how different variables interact under realistic operational constraints. Quality assurance processes included cross-validation of interview data against independent technical sources and a review cycle with subject matter experts to ensure factual accuracy and relevance. Throughout, emphasis was placed on transparency of assumptions, reproducibility of methods, and clear linkage between evidence and recommendations so that readers can adapt insights to their specific strategic and operational contexts.

Concise concluding synthesis emphasizing integration of technical performance, workflow suitability, and supply resilience for enduring diagnostic impact

In summary, parainfluenza diagnostics are converging toward solutions that balance analytical rigor with operational practicality. Advances in immunoassay and molecular methods, coupled with expanding point-of-care capabilities and heightened supply chain awareness, are reshaping how assays are designed, validated, and deployed. Stakeholders must therefore integrate technical performance with considerations around workflow fit, regulatory alignment, and sourcing resilience to achieve sustained clinical impact.

Strategic choices made today regarding platform flexibility, supplier diversification, and regional market alignment will determine the success of diagnostic programs in clinical and public health settings. By focusing on validated performance across relevant sample types and end-user environments, and by proactively engaging with regulatory and procurement processes, organizations can enhance readiness to respond to seasonal surges and emergent respiratory threats while preserving operational stability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Parainfluenza Virus Test Kits Market, by Product

  • 8.1. Isothermal Kits
  • 8.2. Rapid Test Kits
  • 8.3. Real Time Pcr Kits

9. Human Parainfluenza Virus Test Kits Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Chemiluminescence Immunoassay
    • 9.1.2. Enzyme Linked Immunosorbent Assay
    • 9.1.3. Lateral Flow Immunoassay
  • 9.2. Molecular
    • 9.2.1. Isothermal Amplification
    • 9.2.2. Next Generation Sequencing
    • 9.2.3. Real Time Pcr

10. Human Parainfluenza Virus Test Kits Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Point Of Care Centers

11. Human Parainfluenza Virus Test Kits Market, by Sample Type

  • 11.1. Nasopharyngeal Swab
  • 11.2. Oropharyngeal Swab
  • 11.3. Sputum

12. Human Parainfluenza Virus Test Kits Market, by Application

  • 12.1. Clinical Diagnosis
  • 12.2. Epidemiological Surveillance
  • 12.3. Research

13. Human Parainfluenza Virus Test Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Human Parainfluenza Virus Test Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Human Parainfluenza Virus Test Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Human Parainfluenza Virus Test Kits Market

17. China Human Parainfluenza Virus Test Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Anatolia Tani ve Biyoteknoloji Urunleri Sanayi ve Ticaret A.S.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Beijing OriginGene-Tech Biotechnology Co.,Ltd
  • 18.9. BioFire Diagnostics
  • 18.10. bioMerieux SA
  • 18.11. Certest Biotec
  • 18.12. Cortez Diagnostics
  • 18.13. Daan Gene Co., Ltd.
  • 18.14. DBLue Medical
  • 18.15. Genematrix Inc.
  • 18.16. GenMark Diagnostics, Inc.
  • 18.17. Hologic Inc.
  • 18.18. Huwel Lifesciences
  • 18.19. Luminex Corporation
  • 18.20. QIAGEN N.V.
  • 18.21. QuidelOrtho
  • 18.22. R-Biopharm AG
  • 18.23. Roche Holding AG
  • 18.24. Seegene
  • 18.25. Thermo Fisher Scientific
  • 18.26. Xian Tianlong Science and Technology
  • 18.27. Zhejiang Orient Gene

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 151. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 175. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 183. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)